Research Overview
Peptides for Sleep
A research overview of peptides that have been studied in the context of sleep quality, sleep architecture, and circadian regulation.
Sleep quality depends on interrelated processes including growth hormone secretion, circadian signaling, stress axis regulation, and slow-wave sleep architecture. Several peptides have been investigated for effects on these systems, though most evidence remains preliminary.
What This Page Covers
This page examines peptides researched for their potential effects on sleep. The compounds range from a growth hormone secretagogue with incidental sleep architecture data from clinical studies, to neuropeptides specifically designed to influence sleep-related signaling. Evidence quality varies. Some compounds have secondary sleep data from human trials conducted for other indications, while others remain largely preclinical.
How These Peptides May Affect Sleep
Mechanism 01
Growth Hormone Secretion and Sleep Architecture
GH secretagogues may influence slow-wave sleep duration as a secondary effect of stimulating nocturnal growth hormone release, which is naturally coupled to deep sleep phases.
Mechanism 02
Neuropeptide Sleep Signaling
Certain peptides directly target sleep-related neurochemical pathways, including delta-wave inducing signals and pineal gland-associated mechanisms.
Mechanism 03
Stress Axis Modulation
Peptides with anxiolytic or stress-dampening properties may indirectly improve sleep onset and quality by reducing HPA axis hyperactivation.
Peptides Commonly Discussed for Sleep
Ordered by evidence level.
MK-677
Human TrialsGH secretagogue, ghrelin mimetic
GH secretagogue with human trial data showing increased slow-wave sleep duration as a secondary outcome of growth hormone stimulation.
Selank
Animal StudiesAnxiolytic, immune-neuromodulation
Synthetic anxiolytic peptide that may support sleep quality indirectly through stress axis modulation and GABAergic activity.
DSIP
PreclinicalProposed delta-wave sleep signaling
Delta Sleep-Inducing Peptide, originally isolated from rabbit brain. Named for its proposed effect on delta-wave sleep, though human evidence is very limited and inconsistent.
Pinealon
PreclinicalPineal gland peptide bioregulation
Tripeptide researched in the context of pineal gland function and circadian regulation. Data comes primarily from Russian literature.
Quick Comparison
| Peptide | Primary Mechanism | Evidence | Research Context |
|---|---|---|---|
| MK-677 | GH secretagogue, ghrelin mimetic | Human Trials | Human studies show sleep architecture changes; not FDA-approved |
| Selank | Anxiolytic, immune-neuromodulation | Animal Studies | Approved in Russia; indirect sleep relevance through anxiolysis |
| DSIP | Proposed delta-wave sleep signaling | Preclinical | Mostly animal data; human studies small and inconclusive |
| Pinealon | Pineal gland peptide bioregulation | Preclinical | Very limited data; mostly Russian literature |
What the Research Suggests
Best Evidence for Sleep
The most clinically grounded sleep-related peptide data comes from MK-677, where increased slow-wave sleep was observed as a secondary effect in human studies primarily designed to assess growth hormone secretion. Dedicated sleep peptides like DSIP have not produced consistent results in the limited human trials conducted.
Strongest Individual Compound
MK-677 for slow-wave sleep enhancement as a secondary effect of GH secretion stimulation, documented in controlled human studies.
What This Category Cannot Do
MK-677 sleep effects are secondary outcomes, not primary indications. DSIP, despite its name, has produced inconsistent results in human studies and is not established as a reliable sleep intervention. Pinealon data is extremely limited. No peptide covered here is FDA-approved for sleep disorders.
PSI Reading of the Evidence Gap
Sleep research in peptide science covers compounds with indirect sleep-relevant mechanisms and compounds studied specifically for sleep architecture effects. MK-677 has documented slow-wave sleep changes in human studies as a secondary outcome of GH secretagogue activity. DSIP has a specific sleep-related mechanism with effects documented in early research. Epitalon demonstrates circadian rhythm normalization in aging populations. Direct controlled sleep trial data for these compounds in healthy adults remains an important area for future research development.
How to Choose
Research-informed guidance for peptides studied in the context of sleep. Not a recommendation.
Want anxiolytic peptide that may support sleep indirectly
Selank (approved in Russia, not FDA-approved)
Regulatory Status
4 available through compounding.
Important Limitations
Approved Outside US
- Selank: approved in Russia (not for sleep specifically)
Research-Only
- MK-677: investigational GH secretagogue
- DSIP: limited human safety data
- Pinealon: very limited safety data
Key Considerations
MK-677 may increase appetite and affect insulin sensitivity. None of these peptides are FDA-approved for sleep. Individuals with sleep disorders should consult a healthcare provider.
No peptide is FDA-approved for insomnia or sleep disorders.
MK-677 sleep architecture effects are secondary findings from growth hormone studies, not primary sleep endpoints.
DSIP has not produced consistent sleep improvements in the limited human studies conducted.
Pinealon data is confined almost entirely to Russian literature with minimal independent replication.
Established sleep interventions (CBT-I, melatonin, prescription hypnotics) have substantially stronger evidence bases.
Explore More
Related Hubs
Who This May Apply To
Individuals researching whether any peptide compounds have documented effects on sleep quality or architecture.
Healthcare providers evaluating the evidence for peptide-related sleep interventions.
Researchers studying the relationship between growth hormone secretion and sleep architecture.
Related Conditions
This page is provided for educational and informational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. The peptides discussed include both FDA-approved medications and research compounds that are not approved for clinical use. Always consult a qualified healthcare professional before making any decisions about medical treatments. The Peptide Science Institute is an independent research database and does not sell, prescribe, or recommend any compounds.